Wake up to Mike Allen’s AM, the 10 stories driving your day

Stories

The bidding war for Shire

Flemming Ornskov, Shire CEO.
Shire CEO Flemming Ornskov. Photo: Mark Neuling / CNBC/NBCU Photo Bank via Getty Images

Drug maker Shire has rejected three takeover bids from Takeda Pharmaceutical that valued Shire at more than $60 billion, according to multiple reports, and now Allergan appears to be entering the sweepstakes, per Reuters.

The bottom line: Acquiring Shire, a large and profitable firm that makes hyperactivity drugs Adderall and Vyvanse among others, would easily catapult Takeda or Allegan into the ranks of the largest global drug manufacturers.

More stories loading.